Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 13;20(1):136.
doi: 10.1186/s12879-020-4824-3.

Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review

Sabine Vygen-Bonnet  1 , Wiebke Hellenbrand  2 , Edeltraut Garbe  3 , Rüdiger von Kries  4 , Christian Bogdan  5   6 , Ulrich Heininger  7 , Marianne Röbl-Mathieu  8   9 , Thomas Harder  2
Affiliations

Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review

Sabine Vygen-Bonnet et al. BMC Infect Dis. .

Abstract

Background: Infants < 3 months of age are at highest risk for developing severe complications after pertussis. The majority of pregnant women has low concentrations of pertussis-specific antibodies and thus newborns are insufficiently protected by maternally transferred antibodies. Acellular pertussis vaccination during pregnancy was recently implemented in various countries. Here, we assessed the evidence for safety and effectiveness of pertussis vaccination during pregnancy.

Methods: We searched Medline, Embase, and ClinicalTrials.gov from January 1st 2010 to January 10th 2019. We assessed risk of bias (ROB) using the Cochrane ROB tool and ROBINS-I. We evaluated the quality of evidence using the GRADE approach.

Results: We identified 1273 articles and included 22 studies (14 for safety; 8 for effectiveness), comprising 1.4 million pregnant women in safety studies and 855,546 mother-infant-pairs in effectiveness studies. No significant differences between vaccinated and unvaccinated women and their infants were observed for safety outcomes with the exception of fever and chorioamnionitis. Compared to no vaccination, three studies showed a significantly increased relative risk for the presence of the ICD-9 code for chorioamnionitis in electronic patient data after pertussis vaccination. However, no study reported an increased risk for clinical sequelae of chorioamnionitis after vaccination during pregnancy, such as preterm birth or neonatal intensive care unit admission. Vaccine effectiveness against pertussis in infants of immunized mothers ranged from 69 to 91% for pertussis prevention, from 91 to 94% for prevention of hospitalization and was 95% for prevention of death due to pertussis. Risk of bias was serious to critical for safety outcomes and moderate to serious for effectiveness outcomes. GRADE evidence quality was moderate to very low, depending on outcome.

Conclusion: Although an increased risk for a diagnosis of fever and chorioamnionitis was detected in pregnant women after pertussis vaccination, there was no association with a higher frequency of clinically relevant sequelae. Vaccine effectiveness for prevention of infant pertussis, hospitalization and death is high. Pertussis vaccination during pregnancy has an overall positive benefit-risk ratio. In view of the overall quality of available evidence ongoing surveillance of chorioamnionitis and its potential sequelae is recommended when pertussis vaccination in pregnancy is implemented.

Trial registration: PROSPERO CRD42018087814, CRD42018090357.

Keywords: Acellular pertussis vaccine; Chorioamnionitis; Pertussis; Pregnancy; Tdap.

PubMed Disclaimer

Conflict of interest statement

CB, EG, MRM, RvK, SVB, TH, WH declare that there is not conflict of interest related to the topic presented in this paper.

UH is a member of the “Global Pertussis Initiative” (supported by Sanofi Pasteur, USA) and the “Collaboration of European Experts on Pertussis Awareness Generation”, CEEPAG (supported by Sanofi, France).

References

    1. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis. 2017;17(9):974–980. doi: 10.1016/S1473-3099(17)30390-0. - DOI - PubMed
    1. Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2018. Berlin: Robert Koch Institute; 2019.
    1. Cherry JD. Pertussis in Young Infants Throughout the World. Clin Infect Dis. 2016;63(suppl_4):S119–S122. doi: 10.1093/cid/ciw550. - DOI - PMC - PubMed
    1. Baclic O, Tunis M, Rotondo J, Saboui M, Duchesne-Belanger S, Brophy J, Chevalier T, Moffatt C, for the National Advisory Committee on Immunization (NACI) Literature Review on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine: Safety, Immunogenicity and Effectiveness: An Advisory Committee Review Advisory Committee on Immunization (NACI) Ottawa: National Advisory Committee on Immunization (NACI); 2018.
    1. Schielke Anika, Takla Anja, von Kries Rüdiger, Wichmann Ole, Hellenbrand Wiebke. Marked Underreporting of Pertussis Requiring Hospitalization in Infants as Estimated by Capture–Recapture Methodology, Germany, 2013–2015. The Pediatric Infectious Disease Journal. 2018;37(2):119–125. doi: 10.1097/INF.0000000000001698. - DOI - PubMed

Publication types

MeSH terms

Substances